![]()
李乾斌
— 博士生导师
分享到：
-
教师姓名：李乾斌
-
职称：教授
-
职务：博士生导师
-
教师拼音名称：liqianbin
-
所在单位：湘雅药学院
-
学历：博士研究生毕业
-
入职时间：2010-04-22
-
学位：博士学位
-
毕业院校：山东大学
-
在职信息：在职
-
学科：药学
-
招生学科：药学
- Guo Y., Cao M., Li Z., Zhou H., Chen Z., Li Q. Discovery of a novel 2,4-thiazolidinedione derivative as dual inhibitor of beta-catenin/TCF4 interaction and tubulin polymerization in colon cancer cells. Arch Pharm (Weinheim), 2025, 358(3): e2400796.
- Hu X., Wu Y., Yao M., Chen Z., Li Q. The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy. Future Med. Chem., 2025, 17(3): 329-345.
- Hu Y., Wang Y., Tan W., Zhao C., Li M., Xiang S., Liang X., Gao R., Zeng B., Chen Z., Hu L., Li Q. Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. J Med Chem, 2025.
- Le X., Chen Q., Cao S., Hu G., Li Q., Chen Z. Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells. Acta. Pharm., 2025.
- Le X., Chen Q., Wen Q., Cao S., Zhang L., Hu L., Hu G., Li Q., Chen Z. Design, synthesis and optimization of Apcin analogues as Cdc20 inhibitors for triple-negative breast cancer therapy. Eur J Med Chem, 2025, 289: 117434.
- Tan W., Wang Y., Li M., Zhao C., Hu Y., Gao R., Chen Z., Hu L., Li Q. A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model. Eur J Med Chem, 2025, 286: 117266.
- Wei J., Feng W., Chen Q., Li Q., Chen Z. Rational discovery of molecular glue degraders based on block chemistry. Drug Discov Today, 2025, 30(11): 104480.
- Wu Y., Hu X., Wang S., Ouyang H., Yao M., Chen Z., Li Q. Fragment-based discovery, dynamics simulation and pharmacological study of 2-amino-pyrimidine derivative as HIPK2 inhibitor. Chem. Biol. Interact., 2025, 421: 111771.
- Zhao R., Zhao C., Gao R., Cai Q., Li Q., Hu L. Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics. Drug Discov Today, 2025, 30(1): 104287.
- Hu X., Wang S., Fu S., Zeng J., Wu Y., Gong L., Cao Y., Zhang Y., Han Y., Ouyang H., Xiong Y., He X., Cheng J., Zou S., Chen Z., Tao L., Meng J., Huang L., Yuan Q., Peng Z., Li Q. Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease. Eur J Med Chem, 2026, 302(Pt 2): 118353.
教师个人主页
中南大学
访问量：次
返回首页